DiaMedica Therapeutics’ (DMAC) Buy Rating Reaffirmed at HC Wainwright

DiaMedica Therapeutics (NASDAQ:DMAC)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 74.56% from the stock’s previous close.

Separately, Oppenheimer reissued an “outperform” rating and issued a $6.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 16th.

DiaMedica Therapeutics Trading Down 2.7 %

Shares of DiaMedica Therapeutics stock opened at $4.01 on Friday. The company’s 50-day moving average price is $4.30 and its 200-day moving average price is $3.58. DiaMedica Therapeutics has a 12-month low of $2.14 and a 12-month high of $4.95. The company has a market cap of $171.43 million, a price-to-earnings ratio of -7.16 and a beta of 1.46.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of DiaMedica Therapeutics by 26.3% during the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock valued at $2,807,000 after buying an additional 211,351 shares in the last quarter. Geode Capital Management LLC increased its stake in DiaMedica Therapeutics by 29.6% in the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock valued at $1,286,000 after acquiring an additional 70,070 shares during the last quarter. Blue Trust Inc. purchased a new stake in DiaMedica Therapeutics during the third quarter valued at about $185,000. Magnolia Capital Advisors LLC bought a new stake in DiaMedica Therapeutics during the second quarter worth about $87,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of DiaMedica Therapeutics in the 3rd quarter worth about $40,000. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.